1. Scrip

Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer

But Has Ground To Make Up On Tecentriq

 
• By John Davis

An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.  

Flowers
• Source: Shutterstock

A closely watched clinical study involving Merck & Co. Inc.’s anti-PD-1 therapy Keytruda (pembrolizumab) has reported promising results at an interim analysis, in combination with chemotherapy as a first-line therapy for metastatic triple-negative breast cancer.

The pivotal Phase III KEYNOTE-355 study met one of its dual primary endpoints, improving progression-free survival in metastatic triple-negative breast cancer in patients whose

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas